Head-To-Head Review: InterCure (NASDAQ:INCR) vs. NeuroBo Pharmaceuticals (NASDAQ:NRBO)

InterCure (NASDAQ:INCR) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares InterCure and NeuroBo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
NeuroBo Pharmaceuticals	N/A	-189.12%	-122.31%

Volatility & Risk

InterCure has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500.

Insider and Institutional Ownership

8.3% of InterCure shares are held by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares InterCure and NeuroBo Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$272.67 million	0.24	-$16.83 million	N/A	N/A
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47 million	N/A	N/A

NeuroBo Pharmaceuticals has lower revenue, but higher earnings than InterCure.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for InterCure and NeuroBo Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	0	0	0	0	0.00
NeuroBo Pharmaceuticals	0	0	1	0	3.00

NeuroBo Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 352.49%. Given NeuroBo Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe NeuroBo Pharmaceuticals is more favorable than InterCure.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.